Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mahmood Alnahass

Neurology Valparaiso, IN Medical Doctor

NPI 1497756720 CMS profile 158156

1551 Sturdy Rd, Valparaiso, IN 46383

Open in the dashboard

General payments

$20,523

1,059 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mahmood Alnahass of Valparaiso, IN is reported in the CMS Open Payments database as having received $20,523 across 1,059 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,815 148
2024 General $3,568 172
2023 General $3,348 178
2022 General $2,973 156
2021 General $3,236 182
2020 General $1,722 114
2019 General $1,862 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahmood Alnahass
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Mahmood Alnahass were reported at $3,815. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Mahmood Alnahass Neurology median Middle half National median
2019 $1,862 $474 $118–$2,177 $163
2020 $1,722 $367 $82–$2,309 $114
2021 $3,236 $438 $104–$2,547 $132
2022 $2,973 $442 $103–$2,388 $149
2023 $3,348 $464 $119–$2,312 $160
2024 $3,568 $468 $119–$2,323 $164
2025 $3,815 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,045 116 payments
  2. AbbVie, Inc. $1,570 96 payments
  3. Biogen, Inc. $1,081 63 payments
  4. EMD Serono, Inc. $854 39 payments
  5. Teva Pharmaceuticals USA, Inc. $808 61 payments
  6. UCB, Inc. $790 43 payments
  7. Lilly USA, LLC $743 38 payments
  8. Catalyst Pharmaceuticals, Inc. $695 24 payments
  9. Amneal Pharmaceuticals LLC $667 34 payments
  10. Alexion Pharmaceuticals, Inc. $576 18 payments
  11. Other $10,695 527 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,386 1,052 payments
  2. Education $103 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,077 63 payments
  2. KESIMPTA Neurology $866 41 payments
  3. QULIPTA $641 32 payments
  4. KESIMPTA Neuroscience $567 35 payments
  5. MAYZENT $559 46 payments
  6. FYCOMPA $536 16 payments
  7. VUMERITY $512 29 payments
  8. ZEPOSIA $486 21 payments
  9. AIMOVIG $473 23 payments
  10. BAFIERTAM $450 22 payments
  11. Other $15,704 829 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

5,976

Median for Neurology: 833

Drug cost

$1,305,952

Median for Neurology: $202,670

Branded share of claims

25.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Emgality Pen Galcanezumab-Gnlm Brand 152 $137,521
Vumerity Diroximel Fumarate Brand 13 $124,562
Avonex (4 Pack) Interferon Beta-1a Brand 14 $115,556
Ubrelvy Ubrogepant Brand 68 $76,804
Nurtec Odt Rimegepant Sulfate Brand 54 $66,604
Fycompa Perampanel Brand 54 $62,239
Qulipta Atogepant Brand 42 $61,173
Botox Onabotulinumtoxina Brand 38 $57,968
Briviact Brivaracetam Brand 35 $51,652
Aptiom Eslicarbazepine Acetate Brand 28 $46,365

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$144,193

Medicare's payments for the services billed

Medicare patients

636

Average age 73

Services billed

1,537

349 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 33%
Ischemic heart disease 32%
Depression 29%
Chronic kidney disease 27%
COPD 21%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
$413 — —
FYCOMPA
$328 54 —
BAFIERTAM
$232 — —
KISUNLA
$156 — —
VUMERITY
$133 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

1,059 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record